Monopar Therapeutics Inc (MNPR) AI Stock Analysis

• Market Cap: $387.61M
• Dividend Yield: N/A
• Average Volume (3M): 175.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: N/A
• EPS Growth: -73.48%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.64
• Shares Outstanding: 6,692,140
• 10 Day Avg. Volume: 145,427
• 30 Day Avg. Volume: 175,070
• PEG Ratio: -0.98
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.04
• Enterprise Value/Market Cap: -158.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 4.02K
• 1Y Price Target: $111.00
• Price Target Upside: 91.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -3.58
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $53.00 ▼(-8.49% Downside)
• Action: Reiterated Date: 03/28/26
• Date: Action: Reiterated 03/28/26

The score is primarily held back by weak financial performance (pre-revenue profile, persistent losses, and ongoing cash burn) and bearish technical trend signals (trading below key moving averages with negative MACD). A positive offset is the commercialization-oriented executive hire, while valuation support is limited due to negative earnings and no dividend.

Positive Factors

Low leverage

Historically minimal debt reduces insolvency and interest burden, giving management durable financial flexibility to prioritize R&D and strategic partnering. Low leverage supports longer trial timelines and less pressure to cut programs or seek distressed financing over the next 2–6 months.

Negative Factors

Persistent cash burn

Consistent negative operating and free cash flow requires ongoing external financing or milestone-driven partnerships. That structural funding need increases dilution and execution risk, potentially limiting runway for clinical programs and forcing prioritization decisions that affect long-term pipeline development.

Monopar Therapeutics Inc Business Overview & Revenue Model

Company Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal...

Read more

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal...

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Monopar Therapeutics does not have consistent recurring revenue from commercialized (FDA- or other regulator-approved) products. Revenue, if any, is generally derived from non-operating sources typica...

Read more

As a clinical-stage biopharmaceutical company, Monopar Therapeutics does not have consistent recurring revenue from commercialized (FDA- or other regulator-approved) products. Revenue, if any, is generally derived from non-operating sources typica...

Monopar Therapeutics Inc Financial Statement Overview

Breakdown	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-16.70M	-16.16M	-8.83M	-10.54M	-9.13M
Net Income	-13.72M	-15.59M	-8.40M	-10.52M	-9.10M
Balance Sheet
Total Assets	140.72B	60.29M	7.35M	13.23M	20.52M
Cash, Cash Equivalents and Short-Term Investments	61.83B	60.21M	7.27M	13.12M	20.30M
Total Debt	154.92M	0.00	0.00	8.41K	0.00
Total Liabilities	2.89B	5.25M	1.76M	3.14M	1.58M
Stockholders Equity	137.83B	55.04M	5.59M	10.09M	18.94M
Cash Flow
Free Cash Flow	-12.20B	-6.40M	-7.86M	-7.23M	-7.32M
Operating Cash Flow	-12.20B	-6.40M	-7.86M	-7.23M	-7.32M
Investing Cash Flow	-63.45B	-14.34M	4.93M	-4.92M	0.00
Financing Cash Flow	91.57B	59.29M	2.03M	32.87K	10.88M

Monopar Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 57.92
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Positive. The current price of 57.92 is above the 20-day moving average (MA) of 56.54, above the 50-day MA of 57.36, and below the 200-day MA of 61.39, indicating a neutral trend. The MACD of -0.60 indicates Negative momentum. The RSI at 53.87 is Neutral, neither overbought nor oversold. The STOCH value of 63.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MNPR.

Monopar Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VNDA	56 Neutral	$433.26M	-2.36	-49.24%	―	11.12%	-406.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VSTM	49 Neutral	$491.00M	-2.55	-1849.88%	―	33.79%	-26.37%
CRDF	46 Neutral	$114.17M	-4.09	-82.00%	―	-27.29%	16.40%
MNPR	45 Neutral	$387.61M	-35.28	-0.04%	―	―	-73.48%
SLN	44 Neutral	$273.96M	-3.24	-348.47%	―	―	―
MREO	42 Neutral	$50.92M	-1.59	-83.02%	―	―	―

Monopar Therapeutics Inc Corporate Events